218 related articles for article (PubMed ID: 26668132)
21. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
22. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
[TBL] [Abstract][Full Text] [Related]
23. Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.
Lyde RB; Ahn HS; Vo KK; Jarocha DJ; Tkaczynski J; Treffeisen E; Sullivan SK; Camire RM; Sabatino DE; French DL; Poncz M
Blood Adv; 2019 May; 3(9):1368-1378. PubMed ID: 31036722
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
[TBL] [Abstract][Full Text] [Related]
25. The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.
Shi Q; Mattson JG; Fahs SA; Geurts AM; Weiler H; Montgomery RR
Blood Adv; 2020 Jan; 4(1):55-65. PubMed ID: 31899798
[TBL] [Abstract][Full Text] [Related]
26. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.
Hausl C; Ahmad RU; Sasgary M; Doering CB; Lollar P; Richter G; Schwarz HP; Turecek PL; Reipert BM
Blood; 2005 Nov; 106(10):3415-22. PubMed ID: 16091456
[TBL] [Abstract][Full Text] [Related]
27. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
29. Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.
Gao C; Schroeder JA; Xue F; Jing W; Cai Y; Scheck A; Subramaniam S; Rao S; Weiler H; Czechowicz A; Shi Q
Blood Adv; 2019 Sep; 3(18):2700-2711. PubMed ID: 31515232
[TBL] [Abstract][Full Text] [Related]
30. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
31. Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors.
Gewirtz J; Thornton MA; Rauova L; Poncz M
J Thromb Haemost; 2008 Jul; 6(7):1160-6. PubMed ID: 18433455
[TBL] [Abstract][Full Text] [Related]
32. Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice.
Meslier Y; André S; Teyssandier M; Kaveri SV; Lacroix-Desmazes S
Immunology; 2010 Dec; 131(4):549-55. PubMed ID: 20673239
[TBL] [Abstract][Full Text] [Related]
33. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
34. Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.
Lavigne-Lissalde G; Rothschild C; Pouplard C; Lapalud P; Gruel Y; Schved JF; Granier C
Clin Rev Allergy Immunol; 2009 Oct; 37(2):67-79. PubMed ID: 19172415
[TBL] [Abstract][Full Text] [Related]
35. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
[TBL] [Abstract][Full Text] [Related]
36. Immune response to FVIII in hemophilia A: an overview of risk factors.
Ghosh K; Shetty S
Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of inhibitors in mild/moderate haemophilia A.
Peerlinck K; Jacquemin M
Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
39. Nonhuman glycans can regulate anti-factor VIII antibody formation in mice.
Arthur CM; Zerra PE; Shin S; Wang J; Song X; Doering CB; Lollar P; Meeks S; Stowell SR
Blood; 2022 Mar; 139(9):1312-1317. PubMed ID: 34019619
[TBL] [Abstract][Full Text] [Related]
40. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
